Investors Sell Pfizer (PFE) on Strength (PFE)

Investors sold shares of Pfizer (NYSE:PFE) on strength during trading hours on Monday. $75.62 million flowed into the stock on the tick-up and $178.52 million flowed out of the stock on the tick-down, for a money net flow of $102.90 million out of the stock. Of all equities tracked, Pfizer had the 13th highest net out-flow for the day. Pfizer traded up $0.29 for the day and closed at $35.46

PFE has been the subject of several research analyst reports. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a research report on Monday, January 8th. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, January 8th. Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $39.25.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The stock has a market capitalization of $209,362.25, a PE ratio of 13.38, a P/E/G ratio of 1.76 and a beta of 0.90.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same period last year, the firm posted $0.47 EPS. Pfizer’s revenue for the quarter was up .6% compared to the same quarter last year. analysts anticipate that Pfizer will post 2.96 EPS for the current year.

Pfizer declared that its board has authorized a stock repurchase plan on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

In other news, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $36,790. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of Pfizer stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,037 shares of company stock valued at $9,064,785. Insiders own 0.06% of the company’s stock.

Several large investors have recently bought and sold shares of PFE. BlackRock Inc. grew its stake in Pfizer by 2.8% in the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after acquiring an additional 12,183,218 shares during the period. Mackenzie Financial Corp grew its stake in Pfizer by 29,164.7% in the 4th quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock valued at $415,878,000 after acquiring an additional 11,442,753 shares during the period. Janus Henderson Group PLC grew its stake in Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. grew its stake in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Finally, Amundi Pioneer Asset Management Inc. grew its stake in Pfizer by 81.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock valued at $691,583,000 after acquiring an additional 8,563,358 shares during the period. 71.21% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/09/investors-sell-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply